Germany

Germany's primary regulatory authority for health products is the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), with the Paul-Ehrlich-Institut (PEI) overseeing biologicals, vaccines, and blood products. The overarching legislative framework includes the Arzneimittelgesetz (AMG, Medicinal Products Act), the Medizinprodukterecht-Durchführungsgesetz (MPDG, Medical Devices Implementation Act), and EU-level regulations such as Regulation (EU) 2017/745 (MDR) for medical devices and Regulation (EU) 536/2014 for clinical trials. Germany operates within the European Medicines Agency (EMA) framework for centralized marketing authorization of pharmaceuticals, while national procedures (national, mutual recognition, and decentralized) remain available for products not requiring centralized review. Digital health applications (Digitale Gesundheitsanwendungen, DiGA) follow a fast-track pathway administered by BfArM under the Digital Healthcare Act (DVG), with provisional approval possible within 90 days.

Submission requirements vary by product category but generally align with EU harmonized standards. Pharmaceutical dossiers must conform to the Common Technical Document (CTD) format, and medical device submissions require a CE marking under the relevant EU regulation, supported by a notified body (Benannte Stelle) conformity assessment. Manufacturers based outside the EU must appoint an Authorized Representative (EU REP) established within the European Economic Area. Germany has been at the forefront of implementing the EU MDR and In Vitro Diagnostic Regulation (IVDR, EU 2017/746), with transition deadlines enforced progressively since 2021. Recent reforms under the MPDG strengthened post-market surveillance obligations, introduced stricter unique device identification (UDI) requirements, and expanded vigilance reporting mandates. The DVG and its successor legislation (DVPMG) represent a significant legislative evolution, establishing a structured evidence generation and reimbursement pathway specifically for certified digital health applications.

Germany operates a predominantly decentralized, multi-payer procurement structure rooted in its federal system (Bundesstaat). Statutory health insurance (Gesetzliche Krankenversicherung, GKV), which covers approximately 90% of the population, is administered through over 90 non-profit sickness funds (Krankenkassen) operating under the oversight of the Gemeinsamer Bundesausschuss (G-BA, Federal Joint Committee) and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds). The G-BA determines benefit coverage and reimbursement eligibility, while the Gesundheitsministerium (BMG, Federal Ministry of Health) sets overarching policy. For pharmaceuticals, the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) mandates early benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) for all newly approved drugs, with negotiated reimbursement prices between manufacturers and the GKV-Spitzenverband following within 12 months of market launch. Hospitals and public health institutions procure through public tender processes governed by the Vergabeverordnung (VgV) and EU public procurement directives, with federal and state (Lander) authorities each managing their own hospital and outpatient procurement frameworks. Sickness funds also issue selective contracts and rebate agreements (Rabattvertraege) with manufacturers, particularly for generics and biosimilars, creating a highly competitive tendering environment at the fund level.

Private health insurance (Private Krankenversicherung, PKV) covers approximately 10% of the population and generally reimburses at higher tariff rates with fewer procurement restrictions, providing an additional market channel for innovative or premium-positioned health products. Germany does not rely on major multilateral donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi for domestic health product supply, given its status as a high-income country and net contributor to these mechanisms. However, German institutions and manufacturers actively participate in international procurement consortia and export markets supported by these donors. Local manufacturing preference policies are not formally codified in domestic procurement law to the same degree as in some markets; however, European supply chain resilience has become a policy priority following COVID-19 disruptions, with the EU Chips Act analogy driving discussions around critical medicines and medical countermeasures production within the EU. The German government has supported initiatives under the EU Health Emergency Preparedness and Response Authority (HERA) and the European Health Union framework to incentivize onshore or near-shore manufacturing capacity for strategic health products.